Earnings Performance: Medpace Holdings Inc. reported third-quarter earnings of $3.86, exceeding expectations of $3.52, with sales of $659.9 million, surpassing the consensus of $640.99 million and showing a 23.7% year-over-year increase.
Fiscal Guidance Update: The company raised its fiscal 2025 earnings per share guidance to $14.60-$14.86, above the consensus of $14.07, and adjusted sales guidance to $2.48 billion-$2.53 billion compared to the previous consensus of $2.46 billion.
Stock Market Reaction: Following the earnings announcement, Medpace shares rose by 1% to $602.08.
Analyst Ratings Changes: Analysts adjusted their price targets for Medpace, with Mizuho maintaining an Outperform rating and raising the target to $655, while Barclays maintained an Underweight rating and increased the target to $485.
MEDP
$557.07+Infinity%1D
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MEDP is 524.89 USD with a low forecast of 425.00 USD and a high forecast of 655.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast MEDP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MEDP is 524.89 USD with a low forecast of 425.00 USD and a high forecast of 655.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
7 Hold
2 Sell
Hold
Current: 558.740
Low
425.00
Averages
524.89
High
655.00
Current: 558.740
Low
425.00
Averages
524.89
High
655.00
Barclays
Luke Sergott
Underweight
maintain
$485 -> $525
2025-12-15
New
Reason
Barclays
Luke Sergott
Price Target
$485 -> $525
2025-12-15
New
maintain
Underweight
Reason
Barclays analyst Luke Sergott raised the firm's price target on Medpace to $525 from $485 and keeps an Underweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.
BMO Capital
Market Perform
initiated
$600
2025-11-12
Reason
BMO Capital
Price Target
$600
2025-11-12
initiated
Market Perform
Reason
BMO Capital initiated coverage of Medpace with a Market Perform rating and $600 price target. The firm views the stock's valuation as full in a "tepid" biotech funding backdrop. The shares at current levels leave "little cushion for additional potential macro volatility," the analyst tells investors in a research note.
Truist
Jailendra Singh
Hold
maintain
$436 -> $555
2025-10-27
Reason
Truist
Jailendra Singh
Price Target
$436 -> $555
2025-10-27
maintain
Hold
Reason
Truist analyst Jailendra Singh raised the firm's price target on Medpace to $555 from $436 and keeps a Hold rating on the shares after meeting with its management team to discuss Q3 results, book-to-bill targets, and expectations for 2026. The firm's higher assumed forward earnings multiple at 20-tims vs. 18-times prior reflects its increased confidence in the continuing recovery in the Biotech market, the analyst tells investors in a research note.
Baird
Neutral
maintain
$491 -> $613
2025-10-24
Reason
Baird
Price Target
$491 -> $613
2025-10-24
maintain
Neutral
Reason
Baird raised the firm's price target on Medpace to $613 from $491 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results.
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
